WAVE Life Sciences Ltd

1U5

Company Profile

  • Business description

    WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

  • Contact

    7 Straits View No. 12-00
    Marina One East Tower
    Singapore018936
    SGP

    T: +65 62363388

    E: [email protected]

    https://www.wavelifesciences.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    317

Stocks News & Analysis

stocks

ASX energy giant undervalued despite commissioning challenges

Near-term hurdles, long-term upside.
stocks

Undervalued ASX share upgrades guidance

Market share gains drive earnings upgrade despite a weak US housing backdrop.
stocks

ASX major bank drives strong quarterly profit

Profit momentum remains robust yet shares overvalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,097.7065.400.72%
CAC 408,406.0633.780.40%
DAX 4025,361.03262.031.04%
Dow JONES (US)52,210.08262.830.51%
FTSE 10010,781.7545.520.42%
HKSE25,214.677.490.03%
NASDAQ24,932.0843.74-0.18%
Nikkei 22562,338.602,592.59-3.99%
NZX 50 Index13,861.9311.240.08%
S&P 5007,413.181.200.02%
S&P/ASX 2008,933.1070.900.80%
SSE Composite Index3,815.4242.82-1.11%

Market Movers